

Time to move forward: Challenges and Research Opportunities for Lung Cancer Screening and Early Detection in Europe

27–28 January 2022

Lisbon, Portugal

Thursday, 27 January 2022

08.30 – 08.45 Registration

08.45 – 09.00 Introduction – Jan van Meerbeek, BE and Annemiek Snoeckx, BE

Session 1: Update on lung cancer screening: did we make any further progress?

09.00 – 09.20 Two years after NELSON: Are there any further data on subgroup analyses or secondary endpoints? – Harry De Koning, NL

09.20 – 09.30 Status of current ERS driven lung cancer screening initiatives – David Baldwin, UK

09.30 – 09.40 Presentation of the ESTI Lung Cancer Certification Project - Annemiek Snoeckx, BE

09.35 – 10.00 Discussion

10.00 – 10.30 *Coffee break*

10.30 – 12.00 *Break-out session I*

What is currently ongoing in Europe?

- An update on current initiatives in different European countries
Chairs: Jan van Meerbeek
6 minutes per speaker (according to a structured layout that will be delivered to the speakers)
Europe; Croatia; UK; Italy; Germany; France; Norway; Spain; Poland
- How will smoking cessation be integrated into lung cancer screening in your lung cancer screening program?
Chairs: tbc

12.00 – 12.30 Report to the plenary session and discussion

12.30 – 13.15 *Lunch break*

Session 2 - The time to implement is now

13.15 – 13.35 Making research findings more powerful for clinical use – Sabina De Geest, CH

13.35 – 13.55 Role of the GP in lung cancer screening – tbc

13.55 - 14.15 Psychological impact of lung cancer screening – Georgia Hardavella, GR

14.15 – 14.35 The voice of the participant – tbc

14.35 – 15.00 Discussion

15.00 – 16.30 Break out session 2: presentation of research projects in Europe

- **Group 1:** The quest for biomarkers for early lung cancer
Chair: Luis Montuenga and Joanna Chorostowska
- **Group 2:** ERS-task force on handling of screen detected nodules
Chair: David Baldwin and Witold Rzyman

16.30 – 17.00 *Coffee break*

Session 3: The world does not stand still: evolution in imaging and treatment

- 17.00 – 17.20 *Is ultra-low-dose ready for practice?* – Mario Silva, IT
- 17.20 – 17.40 *Research opportunities in nodule handling: robotic surgery and beyond* – Witold Rzyman, PL
- 17.40 – 18.00 *Artificial Intelligence in lung cancer screening* – Colin Jacobs, NL
- 18.00 – 18.30 Discussion

Friday, 28 January 2022

Session 4: Early detection biomarkers: ready for implementation in screening?

- 09.00 – 09.20 *Genomic screening: myths, promises and achievements* – Joanna Chorostowska, PL
- 09.20 – 09.40 *Biomarker performance and pathways to clinical utility* – Luis M. Montuenga, ES
- 09.40 – 10.00 *VOC's for lung cancer screening: where are we now?* – Marc Van Der Schee, NL

10.00 – 10.30 Discussion

10.30 – 11.00 *Coffee break*

11.00 – 12.00 Report from break out session II

- Group 2 + discussion 20'
- Group 3 + discussion 20'

Session 5: Taking research forward in the ERS

- 12.00 – 12.20 *What is the optimal design for trials incorporating biomarkers and CT-scan screening?*
– tbc
- 12.20 – 12.40 *Agenda for an ERS clinical research collaboration* – Jan van Meerbeeck, BE
- 12.40 – 13.00 Remarks, wrap up and action points

13.00 – 14.00 Lunch

Meeting of the Task Force writing committee

All speakers + all chairs